Santiago Grijalvo

Dr. Santiago Grijalvo

CIBER BBN, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
HDHassan Dana
Hassan Dana
EGElahe Gharagouzloo
Elahe Gharagouzloo
SGSantiago Grijalvo
Santiago Grijalvo
Ramon EritjaRamon Eritja
Ramon Eritja
VMVahid Marmari
Vahid Marmari
Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment.

27 February 2017 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
APAsja Pettignano
Asja Pettignano
SGSantiago Grijalvo
Santiago Grijalvo
MHMarleen Häring
Marleen Häring
Ramon EritjaRamon Eritja
Ramon Eritja
Nathalie TanchouxNathalie Tanchoux
Nathalie Tanchoux
DDDavid Diaz
David Diaz
Boronic acid-modified alginate allows the direct formation of biocompatible hydrogels under basic conditions with remarkable injectable, self-healing and multistimuli-responsive properties.

28 January 2016 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
SGSantiago Grijalvo
Santiago Grijalvo
JMJudith Mayr
Judith Mayr
Ramon EritjaRamon Eritja
Ramon Eritja
DDDavid Diaz
David Diaz
Liposome-encapsulated hydrogels have emerged as an attractive strategy for medical and pharmaceutical applications.

1 January 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
GPGustavo Puras
Gustavo Puras
Mohamed Ahmed MashalMohamed Ahmed Mashal
Mohamed Ahmed Mashal
JZJ. Zárate
J. Zárate
MAM. Agirre
M. Agirre
EOEdilberto Ojeda
Edilberto Ojeda
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

22 January 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SGSantiago Grijalvo
Santiago Grijalvo
GPGustavo Puras
Gustavo Puras
JZJon Zárate
Jon Zárate
MSMyriam Sainz-Ramos
Myriam Sainz-Ramos
NQNuseibah AL Qtaish
Nuseibah AL Qtaish
Ramon EritjaRamon Eritja
Ramon Eritja
Cationic niosomes have become important non-viral vehicles for transporting a good number of small drug molecules and macromolecules. Growing interest shown by these colloidal nanoparticles in therapy is determined by their structural similarities to liposomes. Cationic niosomes are usually obtained from the self-assembly of non-ionic surfactant molecules. This process can be governed not only by the nature of such surfactants but also by others factors like the presence of additives, formulation preparation and properties of the encapsulated hydrophobic or hydrophilic molecules. This review is aimed at providing recent information for using cationic niosomes for gene delivery purposes with particular emphasis on improving the transportation of antisense oligonucleotides (ASOs), small interference RNAs (siRNAs), aptamers and plasmids (pDNA).

2 November 2019 in Biotechnology Journal
Verified
Journal Article
Open access
PDF file
SGSantiago Grijalvo
Santiago Grijalvo
MNManuel Nieto-Diaz
Manuel Nieto-Diaz
RMRodrigo Martinez Maza
Rodrigo Martinez Maza
Ramon EritjaRamon Eritja
Ramon Eritja
DDDavid Diaz
David Diaz
Alginate (ALG) is a lineal hydrophilic polysaccharide present in brown algae cell walls, which turns into a gel state when hydrated. Gelation readily produces a series of three dimensional (3D) architectures like fibers, capillaries, and microspheres, used as biosensors and bio‐actuators in a plethora of biomedical applications like drug delivery and wound healing. Hydrogels have made a great impact on regenerative medicine and tissue engineering because they are able to mimic the mechanical properties of natural tissues due to their high water content. Recent advances in neurosciences have led to promising strategies for repairing and/or regenerating the damaged nervous system. Spinal cord injury (SCI) is particularly challenging, owing to its devastating medical, human, and social consequences. Although effective therapies to repair the damaged spinal cord (SC) are still lacking, multiple pharmacological, genetic, and cell‐based therapies are currently under study. In this framework, ALG hydrogels constitute a source of potential tools for the development of implants capable of promoting axonal growth and/or delivering cells or drugs at specific damaged sites, which may result in therapeutic strategies for SCI. In this mini‐review, the current state of the art of ALG applications in neural tissues for repairing the damaged spinal cord is discussed.